Pathogenica Achieves CE Marking for HAI BioDetection Kit
Pathogenica, Inc. has achieved CE marking for its HAI BioDetection kit that runs on the Ion PGM™ benchtop sequencer. This milestone marks the HAI BioDetection CE-IVD kit as the first sequence-based infectious disease diagnostic kit on the market.
The HAI BioDetection CE-IVD kit enables identification of the causative agents of 95% of nosocomial infections in a single assay, enabling clinicians to rapidly take appropriate precautions for specific patients. The assay not only identifies the pathogen but also includes a broad panel of 10 resistance genes (including mecA, vanA, KPC and TEM), enhancing a clinician's ability to choose the appropriate antimicrobial therapy and practice proper antibiotic stewardship.
The HAI BioDetection CE-IVD kit prepares samples for sequencing from DNA extracted from isolates, colonies, positive blood culture, urine, rectal swabs, and stool. This broad array of sample types makes Pathogenica's assay a strong fit for identifying pathogens associated with enteric diseases, bloodstream infections and respiratory disorders - the key profile for HAIs in the US and EU. Furthermore, the assay requires no pre-culturing for urine, rectal swabs, and stool, enabling a streamlined lab workflow and clinically actionable turnaround (12 hours from DNA extraction to results) for patients affected by urinary tract infections or enteric disorders.
“Culture independent sequencing is a great step forward for clinical applications,” said Pathogenica co-founder George Church, Prof. of Genetics at Harvard Medical School. “Pathogenica has delivered a next-generation sequencing diagnostic tool that provides identification and antibiotic resistance information for improved infection control and therapeutic decision making.”
“Thought leaders in infection control departments have been enthusiastic about our rapid high resolution test,” said Adesokan. “Pathogenica produces clinically superior and actionable results more rapidly after sample collection than other technologies such as MALDI-TOF and PFGE, which require pre-cultured samples.”
In validation testing, the HAI BioDetection CE-IVD kit demonstrated a 100% correct identification rate for 771 bacterial samples. From specific clinical specimens, the kit identified 100% of Enterococcus positive rectal swabs, with an 89% detection rate of vanA, and achieved 92% concordance with microbial culture from stool for a broad set of bacterial targets.
Tags: Antibiotic Sensitivity, Enterococci
Date Published: September 6, 2013
First Automated Phenotypic Test for Carbapenemase Producing Organisms
Bruker Acquires MERLIN Adding Speciality AST and ART
FDA-Cleared Liofilchem MIC Test Strip (MTS™) Delafloxacin (DLX)
FDA-Cleared Liofilchem MIC Test Strip (MTS™) Tedizolid (TZD)
New IUL Colony Counter Automatically Adjusts for Colony and Agar Type